Altasciences Featured Webinars

  1. Flipping The Drug Development Industry On Its Head 6/18/2024

    The video dives into the obstacles of the traditional outsourcing relationship between CROs and sponsors, and how Altasciences has broken from tradition to offer an alternative model.

  2. Cognitive, Pharmacodynamic Testing During FIH CNS Trials 5/22/2024

    A comprehensive review of optimal timing and methodologies for cognitive and pharmacodynamic testing during first-in-human trials on CNS-active compounds.

  3. The Path Forward, Altasciences' Approach To Project Management 3/19/2024

    Learn about a unique, integrated program management strategy that can lower your costs and reduce program timelines from lead candidate selection to clinical proof-of-concept by up to 40%.

  4. The Unique Attributes of Psychedelic Drug Development 1/22/2024

    Navigate key considerations for psychedelic clinical development, from FDA recommendations and abuse potential evaluation to blinding and early-phase trial design.

  5. An Overview Of Health Canada's CTA Process 10/24/2023

    Experience expedited timelines by conducting trials in Canada. Our expertise in navigating Health Canada's CTA process ensures smooth and efficient approvals.

  6. The Advantages Of Conducting Early Phase Trials In North America 10/24/2023

    In this webinar, Altasciences discuss the similarities and differences of conducting early phase research in North America versus other geographic regions.

  7. The Benefits Of Conducting A Clinical Trial In Canada 9/19/2023

    Watch this video in which Altasciences’ regulatory experts share key insights on Health Canada’s Clinical Trial Application (CTA) regulatory submission process.

  8. Exploring The FDA's Draft Guidance On Psychedelic Drug Research 7/26/2023

    Discover the crucial insights and methodological adaptations needed to effectively assess the safety, pharmacology, and efficacy of innovative psychedelic compounds designed for specific medical applications.

  9. The Heart Of The Matter: Early Vs. Late QT Prolongation Testing 2/8/2023

    Dr. Beatrice Setnik, Altasciences' Chief Scientific Officer, walks through the differences between early and late QT prolongation testing.

  10. Strategic Considerations For A Successful CNS Clinical Development Pathway 2/7/2023

    Dr. Beatrice Setnik, Chief Scientific Officer at Altasciences, discusses tactics for a successful clinical development pathway for CNS-active drugs.